Well Referenced

Tag: secondary prevention

Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial

The 2013 TACT trial, a double-blind, placebo-controlled study, assessed the efficacy of disodium EDTA chelation therapy in 1,708 patients aged ≥50 years with prior myocardial infarction (MI). Participants received 40 infusions of a chelation solution containing 3 g of disodium EDTA, ascorbate, B vitamins, electrolytes, procaine, and heparin, or placebo.

Read More »
June 26, 2025 No Comments

Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome

This 2024 review article explores the role of low-dose colchicine (0.5 mg daily) as an anti-inflammatory therapy in reducing adverse cardiovascular events following acute coronary syndrome (ACS). Colchicine exerts its effects by inhibiting microtubule polymerization, thereby reducing leukocyte activation and inflammatory responses implicated in atherosclerotic plaque destabilization. Clinical trials, including

Read More »
June 26, 2025 No Comments

The Trial to Assess Chelation Therapy 2 (TACT2): Rationale and Design

This article presents the design and rationale of the TACT2 trial, a randomized, double-blind, placebo-controlled study aiming to confirm the cardiovascular benefits of EDTA chelation therapy observed in diabetic patients in the original TACT trial. Targeting a high-risk population of 1,200 patients with diabetes and prior myocardial infarction, the trial

Read More »
June 26, 2025 No Comments

Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy

This article reviews the role of chronic toxic metal exposure in cardiovascular disease (CVD), highlighting the impact of metal chelation therapy, particularly using edetate disodium, as a secondary prevention method for cardiovascular events. It discusses the findings of the Trial to Assess Chelation Therapy (TACT), which demonstrated that chelation therapy

Read More »
June 26, 2025 No Comments

Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients

This article reviews the potential benefits of edetate disodium (a chelating agent) in post-myocardial infarction (MI) patients, particularly those with diabetes, for secondary prevention. The Trial to Assess Chelation Therapy (TACT) demonstrated that edetate disodium therapy led to significant cardiovascular improvements, especially in diabetic patients, showing comparable or superior benefits

Read More »
June 26, 2025 No Comments